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BACKGROUND Chronic total occlusion (CTO) recanalization is still a
very challenging topic in the ﬁeld of coronary intervention. Data on
the performance of drug eluting stent (DES) with bioresorbable poly-
mer in CTO are limited. The aim of our study is to assess 1-year clinical
outcomes in CTO lesion management in a large worldwide registry.
METHODS In the large, prospective, single-arm, multi-center eNO-
BORI registry, 12139 patients were treated with Nobori DES. Among
them 437 (3.6%) had at least one CTO lesion treated. An independent
clinical events committee adjudicated all endpoint related adverse
events. The primary endpoint was Target Lesion Failure (TLF) at 1 year.
RESULTS CTO patients were on average 60.7 years old and 82.4% are
male, with a history of myocardial infarction, PTCA and cardiac sur-
gery of 45.7%, 34.1% and 6.7%, respectively. 77.6% patients were
hypertensive and 29.5% had diabetes. 68.7% patients were presented
with stable angina while 13.3% had acute coronary syndrome. Lesions
were located in the LAD (38.5%), RCA (37.6%), and LCX (22.6%).
Multiple vessels were treated in 35.0% of patients (2.21.4 lesions
treated per patient) with an average of 1.50.8 stents per lesion.
Among all 751 treated lesions, 614 (81.8%) were complex B2/C type
lesions, with 17.2% Ostial lesion, 49.1% moderate or severe calciﬁed
lesion, 62.6% CTO lesion, 2.8% had thrombus present and 7.3% were
bifurcation. Pre- and post-dilatation were performed in 85.5% and
36.4% of lesions, respectively. Antegrade approach was chosen in the
majority of procedures (88.2%), and a high frequency of single wire
technique (79.0%) was used compared to parallel wire (13.4%) and
seesaw wire (1.5%) techniques. Several other techniques were used for
CTO treatment including CTO dedicated wires (38.4%), OTW balloon
(8.5%), microcatheter (26.8%), rotational atherectomy (2.0%), cutting
balloon (2.9%) and balloon dilatation only (4.7%). IVUS guidance was
performed in 7.4% of patients. The average contrast volume and ﬂu-
oro time were 269124mL and 37.237.9 minutes, respectively. Pro-
cedural success rate was 98.2%. At 1 year follow up, 16 (3.7%) out of
437 patients had TLF. Three cardiac deaths (0.7%) and 7 target lesion
revascularizations (1.6%) were reported at one year follow-up -
together with 7 (1.6%) myocardial infarctions. A total of 80.8% of the
patients were angina free at 1 year. Only 1 stent thrombosis (deﬁnite
plus probable) was reported up to 1 year.
CONCLUSIONS Treatment of CTO with Nobori DES showed encour-
aging outcomes, although we cannot completely exclude the possi-
bility that there might be underreporting of events, particularly
periprocedural MIs might exist. One-year clinical outcomes suggest
that this stent is a valuable treatment option for patients with CTO
who are considered candidates for coronary interventions.
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BACKGROUND Although second generation drug-eluting stents (DES)
have improved angiographic and clinical outcomes over ﬁrst-genera-
tion DESs, clinical efﬁcacy and safety of second-generation DES for
the percutaneous coronary intervention of chronic total occlusion
(CTO) were not well deﬁned.
METHODS We evaluated the 3-years clinical outcomes of 546 patients
treated with second generation DES (everolimus- or zotarolimus-
eluting stent) and 503 with ﬁrst generation DES (sirolimus- or pacli-
taxel- eluting stent) for CTO in Asan Medical Center from 2004 to
2013. The primary endpoint was the incidence of major adverse car-
diac events (MACE) at 3 years, deﬁned as a composite of death,Q-wave myocardial infarction (MI), or target-vessel revascularization
(TVR).
RESULTS The 3-year overall mortality of the second and ﬁrst gener-
ation DES groups were not signiﬁcantly different. (6.41.2% vs.
4.10.9%, P¼0.12). After multivariable adjustment, there was no sig-
niﬁcant difference between patients who received second generation
and ﬁrst generation DES for the risk of MACE. (Hazard ratio [HR] 1.35,
95% conﬁdence interval [CI] 0.85-2.12, P ¼0.20). The risk of death (HR
1.61, 95% CI 0.86-2.99, P ¼0.14), Q-wave MI (HR 1.41, 95% CI 0.40-
4.95, P ¼0.59) and TVR (HR 0.86, 95% CI 0.41-1.76, p¼0.67) were
similar between the two groups. The incidence of deﬁnite/probable
stent thrombosis was comparable (0.7% vs.1.0%, p¼0.65) throughout
the follow-up period.Outcomes Hazard ratio 95% conﬁdence interval P valueMACE 1.35 0.85-2.12 0.20Death 1.61 0.86-2.99 0.14Cardiac death 1.72 0.75-3.95 0.20Myocardial infarction 1.41 0.40-4.95 0.59Death and myocardial infarction 1.50 0.86-2.73 0.16Target vessel revascularization 0.86 0.41-1.76 0.67Any repeat revascularization 1.11 0.64-1.93 0.72MACE ¼ major adverse cardiovascular event.CONCLUSIONS The 3-year clinical outcomes after CTO intervention
using second generation DESs were not signiﬁcantly different from
those using ﬁrst generation DESs.
CATEGORIES CORONARY: Stents: Drug-Eluting
KEYWORDS Chronic total occlusion, Clinical outcomes, Drug-eluting
stent
TCT-587
Bioabsorbable polymer-coated thin strut everolimus-eluting synergy stent
for coronary revascularization in daily clinical practice: One-year results of
the SWEET registry
Serban Puricel,1 Lorenz Raber,2 Dik Heg,3 Mathieu Stadelmann,1
Kyohei Yamaji,2 Thomas Zanchin,2 Philip Urban,4 Estelle Boute,1
Peter Wenaweser,2 Mario Togni,5 Edoardo De Benedetti,6
Stephan Windecker,2 Stéphane Cook1
1University and Hospital Fribourg, Fribourg, Switzerland; 2University
Hospital Bern, Bern, Switzerland; 3Institute of Social and Preventive
Medicine, University of Bern, Bern Switzerland, Bern, Switzerland;
4Hôpital de la Tour, Geneva, Switzerland; 5Hospital and University
Fribourg, Fribourg, Switzerland; 6Hôpital de La Tour, Geneva,
Switzerland
BACKGROUND Bioabsorbable polymer drug-eluting stents (DES)
represent an indisputable improvement over ﬁrst-generation DES
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determine the 1-year clinical follow-up in patients treated with the
bioabsorbable polymer-coated everolimus-eluting SYNERGY stent in
daily clinical routine.
METHODS All consecutive patients treated with the SYNERGY stent at
University and Hospital Fribourg, La Tour Hospital Geneva and the
University Hospital of Bern between December 2012 and June 2014
were prospectively included in the SWEET registry (SWiss Evaluation
of bioabsorbable polymer-coated Everolimus-eluting coronary sTent).
Clinical follow-up was performed at 1 year. The primary endpoint was
the Academic Research Consortium (ARC) deﬁned device-oriented
composite of cardiac death (CD), myocardial infarction of the target
vessel (TV-MI) and clinically indicated target lesion revascularization
(CI-TLR) at 1 year.
RESULTS One thousand patients were included in the SWEET reg-
istry. Intermediate analysis was performed in the ﬁrst 820 patients
(1289 lesions) in whom 1-year follow-up was available. Mean age
was 6811 years and 73% (n¼569) of patients were men. Diabetes
mellitus was present in 22% (n¼178) and a history of previous
myocardial infarction in 18% (n¼147) of patients. Acute Coronary
Syndrome was the indication for stent implantation in 55% (n¼451)
of cases of which 22% (n¼184) presented with STEMI. Median (25th-
75thpercentile) SYNTAX score was 13 (7-21). Left main treatment was
performed in 4% (n¼30) and saphenous vein graft interventions in
3% (n¼22) of patients. The primary endpoint occurred in 9.3%
(n¼76) of patients at 1 year (Figure 1). CD was 4.9% (n¼40) and TV-
MI occurred in 2.7% (n¼22) of patients. CI-TLR was performed in
4.0% (n¼33) of patients. The ARC-deﬁned patient-oriented com-
posite end point (all-cause mortality, any myocardial infarction, any
revascularization) occurred in 15.2% (n¼125) of patients at 1 year.
ARC-deﬁned deﬁnitive stent thrombosis occurred in 14 patients
(1.7%) within the ﬁrst year after stent implantation (early: 1.6%
[n¼13], late 0.1% [n¼1]).
CONCLUSIONS The bioabsorbable polymer-coated thin strut ever-
olimus-eluting SYNERGY stent yields a favorable safety and efﬁcacy in
daily clinical practice.
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BACKGROUND Newer generation of drug eluting stents (DES) has
attempted to improve safety using abluminal sirolimus drug de-
livery with biodegradable polymers matrix. Abluminus is siroli-
mus eluting stent with biodegradable polymer matrix coated on
abluminal stent and parts balloon surface. The aim of en-ABL
e-registry is to capture long term clinical data of the Abluminus by
evaluation of safety and efﬁcacy in large population in routine
clinical practice.
METHODS The study is designed for all-comers by the prospective
method in 3000 patients in India. The data was divided in 3 sub-set
of patient; diabetic (n¼300), MVD (n¼200) and long lesion (n¼200)
subsets. Primary endpoint was major adverse cardiac events
(MACE); deﬁned as composite of cardiac death, myocardial infarc-
tion (MI), cardiac / non-cardiac death, target lesion revascularization
(TLR) and target vessel revascularization (TVR) at 12 months. Major
secondary endpoints were stent thrombosis (deﬁnite and probable
according to ARC conditions) as acute, sub-acute and late
thrombosis.
RESULTS We evaluated 1026 prospective patients 1342 devices and
corresponding 1229 lesions. Mean age of population was 56.21 
10.63%, 81.77% were male, 36.65% patients were diabetic, small
vessel < 2.5 mm were 49.87% and long lesion > 28 mm were 50.12%.
Individual time domain % MACE are reported in table 1. One acute and
one sub-acute stent thrombus events was reported.
Table 1. Individual adverse events (%) at different time pointsFollow-up 1 month 3 months 9 months 12 months 24 monthsPatients – follow-up 1020 963 798 692 157Angiographic follow-up – – 99 – –MACE 0.10 0.19 1.35 0.1 0.1Death 0 0 0 0 0Cardiac death 0 0 0 0 0MI 0 0 0 0 0TVR/TLR 0.1 0.19 1.35 0.1 0.1CONCLUSIONS Interim analysis has revealed a MACE rate 1.64% at
9 month follow-up and 2 events of stent which remains unchanged
at 2 year follow-up. The data suggests safety and efﬁcacy of DES in
routine clinical practice. Further data will be presented during
conference.
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BACKGROUND The inﬂuence of diabetes mellitus (DM) on the clinical
outcomes after PCI for the multi-vessel coronary artery disease (CAD)
using drug eluting stent (DES) were not well deﬁned to date.
METHODS We evaluated the clinical outcomes after PCI using DES for
multi-vessel CAD in patients with or without DM. From January 2003
to December 2013, a total of 5057 patients underwent PCI for the
multi-vessel CAD with (n¼1738) or without (n¼3319) DM were
included. The primary outcome was the incidence of major adverse
